(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 6.8% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Zoetis's revenue in 2024 is $8,544,000,000.On average, 7 Wall Street analysts forecast ZTS's revenue for 2024 to be $4,192,123,248,301, with the lowest ZTS revenue forecast at $4,180,166,506,460, and the highest ZTS revenue forecast at $4,209,666,884,679. On average, 7 Wall Street analysts forecast ZTS's revenue for 2025 to be $4,483,982,399,150, with the lowest ZTS revenue forecast at $4,439,021,679,925, and the highest ZTS revenue forecast at $4,537,156,338,683.
In 2026, ZTS is forecast to generate $4,762,234,655,075 in revenue, with the lowest revenue forecast at $4,665,208,034,735 and the highest revenue forecast at $4,872,667,624,542.